Abstract 144P
Background
This study was conducted to evaluate the relation of DNA damage repair (DDR) to clinical outcomes in gastric cancer patients with stage II or III treated gastrectomy.
Methods
From January 2005 to December 2017, 217 patients with stage II or III gastric cancer were analyzed for disease free survival (DFS) and overall survival according to DDR gene status. Immunohistochemical assessment of MLH1, MSH2, ARID1A, PARP-1, BRCA1 and ATM was performed in biologic samples.
Results
Among the 217 patients, the most commonly mutated DDR gene was MSH2 (n = 208, 95.9%), followed by BRCA1 (n = 191, 88.0%), MLH1 (n = 184, 84.8%), ARID1A (n = 170, 78.3%), ATM (n = 146, 67.3%) and PARP-1 (n=120, 55.3%). The high expression levels of PARP-1 group had a significantly longer 5-year OS rate as compared to low expression level of PARP-1 group (62.7% vs. 48.1%, HR 0.649, 95% CI 0.433-0.974, P = 0.035). In the multivariate OS analysis, TNM stage (HR = 5.202, P < 0.001), high expression PARP-1 (HR = 0.583, P = 0.011) and adjuvant chemotherapy (HR = 0.382, P <0.001) were only significantly prognostic factor.
Conclusions
A subgroup of patients with gastric cancer may benefit from targeted therapy. High PARP-1 expression may be a good prognostic factor for gastric cancer particularly, stage II or III gastric cancer post-surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session